Table: monthly_update_prescription_drugs_intro_to_the_market_excel , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Biocon Biologics Inc.	83257002611	Yesintek 130 mg/26 mL (5 mg/mL) injection in an SDV	2025-02-22	399.9900	None	1	18831	None	None	None	None	None	None	None	None
Biocon Biologics Inc.	83257002341	Yesintek 45 mg/0.5 mL injection in a single-dose prefilled syringe	2025-02-22	1499.9900	None	1	10739	None	None	None	None	None	None	None	None
Biocon Biologics Inc.	83257002411	Yesintek 45 mg/0.5 mL injection in an SDV	2025-02-22	1499.9900	None	1	14199	None	None	None	None	None	None	None	None
Biocon Biologics Inc.	83257002541	Yesintek 90 mg/mL injection in a single-dose prefilled syringe	2025-02-22	2999.9800	None	1	96231	None	None	None	None	None	None	None	None
Biocon Limited	70377008711	Dasatinib Tablets 100mg 30ct	2025-03-03	12480.4900	None	1	66000	None	None	None	None	None	None	None	None
Biocon Limited	70377008811	Dasatinib Tablets 140mg 30ct	2025-03-03	12480.4900	None	1	66000	None	None	None	None	None	None	None	None
Biocon Limited	70377008311	Dasatinib Tablets 20mg 60ct	2025-03-03	6924.6500	None	1	66000	None	None	None	None	None	None	None	None
Biocon Limited	70377008411	Dasatinib Tablets 50mg 60ct	2025-03-03	13894.2700	None	1	66000	None	None	None	None	None	None	None	None
Biocon Limited	70377008511	Dasatinib Tablets 70mg 60ct	2025-03-03	13894.2700	None	1	66000	None	None	None	None	None	None	None	None
Biocon Limited	70377008611	Dasatinib Tablets 80mg 30ct	2025-03-03	12480.4900	None	1	66000	None	None	None	None	None	None	None	None
Breckenridge Pharmaceutical	51991099028	EVEROLIMUS TFOS 2MG 4X7	2025-02-01	12894.9800	No Marketing plan currently in place	None	37	None	None	None	None	None	None	None	None
Breckenridge Pharmaceutical	51991099128	EVEROLIMUS TFOS 3MG 4X7	2025-02-01	13024.1400	No Marketing plan currently in place	None	27	None	None	None	None	None	None	None	None
Breckenridge Pharmaceutical	51991099228	EVEROLIMUS TFOS 5MG 4X7	2025-02-01	13555.5200	No Marketing plan currently in place	None	52	None	None	None	None	None	None	None	None
Bristol Myers Squibb	00003612001	Opdivo Qvantig™ 600 mg-10,000 unit/5mL (VIAL (ML))	2025-01-02	7787.3300	We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	840	None	None	None	None	None	None	Estimated number of patients reflects the 2025 average monthly total patients including new and continuing patients from prior months.	None